A comparison between two strategies for monitoring hepatic function during antituberculous therapy

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 6, 2012, Pages 653-659

  Singanayagam, Aran ^a   Sridhar, Saranya ^b   Dhariwal, Jaideep ^a   Abdel Aziz, Dalia ^a   Munro, Kerry ^a   Connell, David W ^b   George, Peter M ^a   Molyneaux, Philip L ^a   Cooke, Graham S ^c   Burroughs, Andrew K ^d   Lalvani, Ajit ^b   Wickremasinghe, Melissa ^a   Kon, Onn Min ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Hepatotoxicity; Liver function; Monitoring; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; TUBERCULOSTATIC AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STRATEGIC PLANNING; TERTIARY HEALTH CARE; TOXIC HEPATITIS;

ADULT; ALANINE TRANSAMINASE; ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TUBERCULOSIS;

EID: 84858255939     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201105-0850OC     Document Type: Article

References (33)

1. Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis treatment: an 11 year study. Tuber Lung Dis 1996;77:335-340.
2. Yee D, Valiqueete C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472-1477. (Pubitemid 37363354)
3. Sharifzadeh M, Rasoulinejad M, Valipour F, Nouraie M, Vaziri S. Evaluation of patient-related factors associated with causality, preventability and severity of hepatotoxicity during antituberculosis treatment. Pharmacol Res 2005;51:353-358. (Pubitemid 40430809)
4. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampicin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996;9:2026-2030. (Pubitemid 26333539)
5. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916-919. (Pubitemid 35193218)
6. Van Hest R, Baars H, Kik S, van Gerven P, Trompenaars MC, Kalisvaart N, Keizer S, Borgdorff M, Mensen M, Cobelens F. Hepatotoxicity of rifampicin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis 2004;39:488-496. (Pubitemid 39120923)
7. Breen RA, Miller RF, Gorusch T, Smith CJ, Schwenk A, Holmes W, Ballinger J, Swaden L, Johnson MA, Cropley I, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 2006;61:791-794. (Pubitemid 44369404)
8. Tost JR, Vidal R, Cayla J, Diaz-Cabanela D, Jimenez A, Broquetas JM. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis 2005;9:534-540. (Pubitemid 40646839)
9. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, et al.; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS Statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-952.
10. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to date review. J Gastroenterol Hepatol 2008;23:192-202. (Pubitemid 351257678)
11. Black M, Mitchell JR, Zimmerman MJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 144 patients. Gastroenterology 1975;69:289-302.
12. Agal S, Baijal R, Pramanik S, Patel N, Gupte P, Kamani P, Amarapurkar D. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 2005;20:1745-1752. (Pubitemid 43961083)
13. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampicin vs isoniazid for the treatment of latent tuberculosis. Chest 2003;123:102-106.
14. Thompson NR, Caplin ME, Hamilton MI, Gillespie SH, Clarke SW, Burroughs AK, McIntyre N. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995;8:1384-1388.
15. Ormerod LP, Skinner C, Wales J. Hepatotoxicity of antituberculosis drugs. Thorax 1996;51:111-113. (Pubitemid 26058148)
16. The 2011 NICE guidelines development group. NICE guidelines. Tuberculosis: clinical diagnosis and management of tuberculosis and measures for its prevention and control [Internet; created 2006; revised 2011; accessed 2011 Nov]. Available from: http://guidance.nice.org.uk/CG117
17. Wu JC, Lee SD, Yeh PF, Chan CY, Wang YJ, Huang YS, Tsai YT, Lee PY, Ting LP, Lo KJ. Isoniazid-rifampicin induced hepatitis in hepatitis B carriers. Gastroenterology 1990;98:502-504.
18. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, Tam CM, Leung CC, Lai CL. Antituberculous drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000;31:201-206.
19. Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CL, Lin TP, Lee SD. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997;12:87-91.
20. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE. Anti-tuberculosis drug induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998;157:1871-1876.
21. Nader LA, de Mattos AA, Picon PD, Bassanesi SL, De Mattos AZ, Pineiro Rodriguez M. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor? Ann Hepatol 2010;9:70-74.
22. Chien JY, Huang RM, Wang JY, Ruan SY, Chien YJ, Yu CJ, Yang PC. Hepatitis C virus infection increases hepatitis risk during antituberculosis treatment. Int J Tuberc Lung Dis 2010;14:616-621.
23. Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, Picon PD, Santos AR, Teixeira RL, Gregianini TS, Hutz MH, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008;64:673-681.
24. Dossing M, Wilcke J, Askgaard DS, Nybo B. Liver injury during anti-tuberculosis treatment: an 11 year study. Tuber Lung Dis 1996;77:335-340. (Pubitemid 26258538)
25. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: case-control study. Thorax 1996;51:132-136. (Pubitemid 26060649)
26. Pessayre D, Bentata M, Degott C, Nouel O, Miguet JP, Rueff B, Benhamou JP. Isoniazid-rifampicin fulminant hepatitis. Gastroenterology 1977;72:284-289.
27. Ozick LA, Jacob L, Comer GM, Lee TP, Ben-Zvi J, Donelson SS, Felton CP. Hepatotoxicity from isoniazid and rifampin in inner city AIDS patients. Am J Gastroenterol 1995;90:1978-1980.
28. Walker NF, Kliner M, Turner D, Bhagani S, Cropley I, Hopkins S, Lipman M. Hepatotoxicity and antituberculosis therapy: time to revise UK guidance? Thorax 2009;64:918.
29. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments: rationale for monitoring liver status. Drug Saf 1996;15:394-405.
30. Riska N. Hepatitis cases in isoniazid treated groups and in a control group. Bull Int Union Tuberc 1976;51:203-208.
31. Seneratne WV, Pinidiyapathirage MJ, Perera G, Wickremasinghe AR. Anti-tuberculosis drug induced hepatitis - a Sri Lankan experience. Ceylon Med J 2006;51:9-13.
32. Baghaei P, Tabarsi P, Chitsaz E, Saleh M, Marjani M, Shemirani S, Pooramiri MV, Kazempour M, Farnia P, Fahimi F, et al. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. Am J Ther 2010;17:17-22.
33. Chaudhry SI, Herrin J, Phillips C, Butler J, Mukerjhee S, Murillo J, Onwuanyi A, Seto TB, Spertus J, Krumholz HM. Racial disparities in health literacy and access to care among heart failure patients. J Card Fail 2011;17:122-127.